Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Marcus

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 31, 2022
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical TrialsJesse G Dixon, Çağlar Çağlayan, Dai Chihara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy eraSilvia Montoto, Kate Shaw, Jessica Okosun, et al.
The New England Journal of Medicine|October 5, 2017
Obinutuzumab for the First-Line Treatment of Follicular LymphomaRobert Marcus, Andrew Davies, Kiyoshi Ando, et al.
Pediatric Blood & Cancer|December 30, 2017
Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group studyJulio C Barredo, Caroline Hastings, Xiamin Lu, et al.
Blood|October 6, 2021
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trialsCarla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with ImmunochemotherapyMagdalena Klanova, Mikkel Z Oestergaard, Marek Trněný, et al.
Blood Advances|March 22, 2021
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trialsCarla Casulo, Jesse G Dixon, Fang-Shu Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM StudyChristiane Pott, Vindi Jurinovic, Judith Trotman, et al.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized TrialsQian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Clinical Lymphoma, Myeloma & Leukemia|August 31, 2022
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical TrialsJesse G Dixon, Çağlar Çağlayan, Dai Chihara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy eraSilvia Montoto, Kate Shaw, Jessica Okosun, et al.
The New England Journal of Medicine|October 5, 2017
Obinutuzumab for the First-Line Treatment of Follicular LymphomaRobert Marcus, Andrew Davies, Kiyoshi Ando, et al.
Pediatric Blood & Cancer|December 30, 2017
Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group studyJulio C Barredo, Caroline Hastings, Xiamin Lu, et al.
Blood|October 6, 2021
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trialsCarla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with ImmunochemotherapyMagdalena Klanova, Mikkel Z Oestergaard, Marek Trněný, et al.
Blood Advances|March 22, 2021
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trialsCarla Casulo, Jesse G Dixon, Fang-Shu Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM StudyChristiane Pott, Vindi Jurinovic, Judith Trotman, et al.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized TrialsQian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.
Pageof 10